Test Bank: Pharmacotherapeutics for Advanced
Practice: A Practical Approach (5th Edition) by
Arcangelo – All Chapters Complete Questions &
Detailed Verified Rationales
SECTION 1: ISSUES FOR THE PRACTITIONER IN DRUG
THERAPY
Chapter 1: Issues for the Practitioner in Drug Therapy
Question 1:
Criteria for choosing an effective drug for a disorder include:
,A) Asking the patient what drug they think would work best for them
B) Consulting nationally recognized guidelines for disease management
C) Prescribing medications that are available as samples before writing a prescription
D) Following U.S. Drug Enforcement Administration (DEA) guidelines for prescribing
Answer: B) Consulting nationally recognized guidelines for disease management
Rationale: Evidence-based practice requires consulting nationally recognized
guidelines (e.g., JNC-8 for hypertension, ADA for diabetes) when selecting
drug therapy. Patient preference is important but not the primary criterion
for efficacy. DEA guidelines address controlled substance regulations, not
general drug selection.
Question 2:
Nurse practitioner practice may thrive under health-care reform due to:
A) The demonstrated ability of nurse practitioners to control costs and improve patient
outcomes
B) The fact that nurse practitioners will be able to practice independently
C) The fact that nurse practitioners will have full reimbursement under health-care
reform
D) The ability to shift accountability for Medicaid to the state level
Answer: A) The demonstrated ability of nurse practitioners to control costs and
improve patient outcomes
Rationale: Research consistently demonstrates that NPs provide high-
quality, cost-effective care with excellent patient outcomes, making them
, valuable in value-based healthcare models. Independent practice and
reimbursement vary by state .
Question 3:
The U.S. Food and Drug Administration (FDA) MedWatch system is activated when:
A) There is an adverse event to a vaccine
B) The patient has a severe reaction that is noted in the "Severe Reaction" section in the
medication label
C) A lactating woman takes a medication that is potentially toxic to the breastfeeding
infant
D) An adverse event or serious problem occurs with a medication that is not already
identified on the label
Answer: D) An adverse event or serious problem occurs with a medication that is
not already identified on the label
Rationale: MedWatch is the FDA's safety information and adverse event
reporting program. It is used to report serious adverse events, product
quality problems, or therapeutic failures—especially those not already
identified on the product labeling. Vaccines have a separate system
(VAERS) .
Question 4:
, The benefits to the patient of having an APRN prescriber include:
A) Nurses know more about pharmacology than other prescribers because they take it
both in their basic nursing program and in their APRN program
B) Nurses care for the patient from a holistic approach and include the patient in
decision-making regarding their care
C) APRNs are less likely to prescribe narcotics and other controlled substances
D) APRNs are able to prescribe independently in all states, whereas a physician's
assistant needs a supervising physician
Answer: B) Nurses care for the patient from a holistic approach and include the
patient in decision-making regarding their care
Rationale: APRNs are trained to provide holistic, patient-centered care that
involves the patient in decision-making. This approach improves patient
satisfaction and adherence. The other options contain inaccuracies about
knowledge, prescribing habits, or practice authority.
Question 5:
Nurse practitioner (NP) prescriptive authority is regulated by:
A) The National Council of State Boards of Nursing
B) The U.S. Drug Enforcement Administration
C) The State Board of Nursing for each state
D) The State Board of Pharmacy
Answer: C) The State Board of Nursing for each state
Rationale: Prescriptive authority for NPs is regulated at the state level by
each state's Board of Nursing, leading to state-by-state variation in practice.
The DEA regulates controlled substances at the federal level but does not
Practice: A Practical Approach (5th Edition) by
Arcangelo – All Chapters Complete Questions &
Detailed Verified Rationales
SECTION 1: ISSUES FOR THE PRACTITIONER IN DRUG
THERAPY
Chapter 1: Issues for the Practitioner in Drug Therapy
Question 1:
Criteria for choosing an effective drug for a disorder include:
,A) Asking the patient what drug they think would work best for them
B) Consulting nationally recognized guidelines for disease management
C) Prescribing medications that are available as samples before writing a prescription
D) Following U.S. Drug Enforcement Administration (DEA) guidelines for prescribing
Answer: B) Consulting nationally recognized guidelines for disease management
Rationale: Evidence-based practice requires consulting nationally recognized
guidelines (e.g., JNC-8 for hypertension, ADA for diabetes) when selecting
drug therapy. Patient preference is important but not the primary criterion
for efficacy. DEA guidelines address controlled substance regulations, not
general drug selection.
Question 2:
Nurse practitioner practice may thrive under health-care reform due to:
A) The demonstrated ability of nurse practitioners to control costs and improve patient
outcomes
B) The fact that nurse practitioners will be able to practice independently
C) The fact that nurse practitioners will have full reimbursement under health-care
reform
D) The ability to shift accountability for Medicaid to the state level
Answer: A) The demonstrated ability of nurse practitioners to control costs and
improve patient outcomes
Rationale: Research consistently demonstrates that NPs provide high-
quality, cost-effective care with excellent patient outcomes, making them
, valuable in value-based healthcare models. Independent practice and
reimbursement vary by state .
Question 3:
The U.S. Food and Drug Administration (FDA) MedWatch system is activated when:
A) There is an adverse event to a vaccine
B) The patient has a severe reaction that is noted in the "Severe Reaction" section in the
medication label
C) A lactating woman takes a medication that is potentially toxic to the breastfeeding
infant
D) An adverse event or serious problem occurs with a medication that is not already
identified on the label
Answer: D) An adverse event or serious problem occurs with a medication that is
not already identified on the label
Rationale: MedWatch is the FDA's safety information and adverse event
reporting program. It is used to report serious adverse events, product
quality problems, or therapeutic failures—especially those not already
identified on the product labeling. Vaccines have a separate system
(VAERS) .
Question 4:
, The benefits to the patient of having an APRN prescriber include:
A) Nurses know more about pharmacology than other prescribers because they take it
both in their basic nursing program and in their APRN program
B) Nurses care for the patient from a holistic approach and include the patient in
decision-making regarding their care
C) APRNs are less likely to prescribe narcotics and other controlled substances
D) APRNs are able to prescribe independently in all states, whereas a physician's
assistant needs a supervising physician
Answer: B) Nurses care for the patient from a holistic approach and include the
patient in decision-making regarding their care
Rationale: APRNs are trained to provide holistic, patient-centered care that
involves the patient in decision-making. This approach improves patient
satisfaction and adherence. The other options contain inaccuracies about
knowledge, prescribing habits, or practice authority.
Question 5:
Nurse practitioner (NP) prescriptive authority is regulated by:
A) The National Council of State Boards of Nursing
B) The U.S. Drug Enforcement Administration
C) The State Board of Nursing for each state
D) The State Board of Pharmacy
Answer: C) The State Board of Nursing for each state
Rationale: Prescriptive authority for NPs is regulated at the state level by
each state's Board of Nursing, leading to state-by-state variation in practice.
The DEA regulates controlled substances at the federal level but does not
